Bladder cancer updates from the first half of 2026

Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results

P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer

Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

The evolving treatment landscape in immune thrombocytopenia

Highlights from APCCC 2026

ASCO 2026: Updates in bladder cancer